{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:31:35Z","timestamp":1789057895246,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral Biology and Craniofacial Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jobcr.2021.02.009","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T06:27:31Z","timestamp":1614061651000},"page":"291-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review"],"prefix":"10.1016","volume":"11","author":[{"given":"Shankargouda","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Gs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi S.","family":"Sarode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin C.","family":"Sarode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki Abdu","family":"Khurayzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiid Elshafey","family":"Mohamed Beshir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol R.","family":"Gadbail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Gondivkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jobcr.2021.02.009_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jobcr.2021.02.009_bib2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1007\/s10067-016-3513-5","article-title":"Public health awareness of autoimmune diseases after the death of a celebrity","volume":"36","author":"Bragazzi","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.jobcr.2021.02.009_bib3","first-page":"13","article-title":"Mechanisms by which B cells and regulatory T cells influence development of murine organ-specific autoimmune diseases","volume":"6","author":"Ellis","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40496-019-0203-9","article-title":"Autoimmunity and the oral cavity","volume":"6","author":"Reilly","year":"2019","journal-title":"Current Oral Health Reports"},{"issue":"12","key":"10.1016\/j.jobcr.2021.02.009_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/nri2438","article-title":"Immunotherapy of autoimmunity and cancer: the penalty for success","volume":"8","author":"Caspi","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.jobcr.2021.02.009_bib6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2567.2001.01335.x","article-title":"Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?","volume":"104","author":"Peakman","year":"2001","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.jobcr.2021.02.009_bib7","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2337\/db08-0420","article-title":"Targeting CD22 reprograms B-cells and reverses autoimmune diabetes","volume":"57","author":"Fiorina","year":"2008","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.jobcr.2021.02.009_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","article-title":"CD20-depleting therapy in autoimmune diseases: from basic research to the clinic","volume":"267","author":"Perosa","year":"2010","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jobcr.2021.02.009_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fimmu.2018.00622","article-title":"B\u00a0cell modulation strategies in autoimmune diseases: new concepts","volume":"9","author":"Musette","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jobcr.2021.02.009_bib10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/17469872.3.3.259","article-title":"CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab","volume":"3","author":"Schmidt","year":"2008","journal-title":"Expet Rev Dermatol"},{"issue":"6","key":"10.1016\/j.jobcr.2021.02.009_bib11","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmunity Highlights"},{"key":"10.1016\/j.jobcr.2021.02.009_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","article-title":"Rituximab: expanding role in therapy for lymphomas and autoimmune diseases","volume":"55","author":"Rastetter","year":"2004","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.jobcr.2021.02.009_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituxim\u2217ab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jobcr.2021.02.009_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2169\/internalmedicine.46.1914","article-title":"Cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune disease","volume":"46","author":"Tanaka","year":"2007","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/sonc.2002.30149","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)","volume":"29","author":"Leonard","year":"2002","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.jobcr.2021.02.009_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/08830185.2012.709890","article-title":"CD22 and autoimmune disease","volume":"31","author":"D\u00f6rner","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"2","key":"10.1016\/j.jobcr.2021.02.009_bib19","first-page":"1500","article-title":"Anti-CD22 epratuzumab for systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Li","year":"2019","journal-title":"Exp.Therapeut.Med."},{"issue":"17","key":"10.1016\/j.jobcr.2021.02.009_bib20","first-page":"3020","article-title":"Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood","volume":"122","author":"Rossi","year":"2013","journal-title":"J.\u00a0Am. Soc.Hematol."},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/25785826.2019.1698929","article-title":"B\u00a0cells targeting therapy in the management of systemic lupus erythematosus","volume":"43","author":"Lee","year":"2020","journal-title":"Immunological Medicine"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.jobcr.2021.02.009_bib23","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib24","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"10.1016\/j.jobcr.2021.02.009_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"2","key":"10.1016\/j.jobcr.2021.02.009_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2169\/internalmedicine.38.178","article-title":"Anticytokine therapy in autoimmune diseases","volume":"38","author":"Nishimoto","year":"1999","journal-title":"Intern Med"},{"issue":"9","key":"10.1016\/j.jobcr.2021.02.009_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.7150\/ijbs.4666","article-title":"Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases","volume":"8","author":"Tanaka","year":"2012","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.jobcr.2021.02.009_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch Immunol Ther Exp"},{"issue":"2","key":"10.1016\/j.jobcr.2021.02.009_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jobcr.2021.02.009_bib30","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A\u00a052-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jobcr.2021.02.009_bib31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.jobcr.2021.02.009_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jcph.312","article-title":"Population exposure\u2013response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis","volume":"54","author":"Tham","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv.Chronic Dis."},{"issue":"11","key":"10.1016\/j.jobcr.2021.02.009_bib34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2217\/imt.15.79","article-title":"Manipulating regulatory T cells: a promising strategy to treat autoimmunity","volume":"7","author":"Zhang","year":"2015","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.jobcr.2021.02.009_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/erv.12.146","article-title":"T-cell-based immunotherapy of autoimmune diseases","volume":"12","author":"Ulivieri","year":"2013","journal-title":"Expet Rev Vaccine"},{"key":"10.1016\/j.jobcr.2021.02.009_bib36","first-page":"1","article-title":"Antigen-based immunotherapy for autoimmune disease: current status","volume":"4","author":"Hirsch","year":"2015","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.jobcr.2021.02.009_bib37","article-title":"Autoimmune diseases and their manifestations on oral cavity: diagnosis and clinical management","volume":"2018","author":"Saccucci","year":"2018","journal-title":"J.\u00a0Immunol.Res."},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"15","key":"10.1016\/j.jobcr.2021.02.009_bib39","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jobcr.2021.02.009_bib40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jobcr.2021.02.009_bib41","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Maglie","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jobcr.2021.02.009_bib42","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bjd.17577","article-title":"Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies","volume":"180","author":"Kwatra","year":"2019","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jobcr.2021.02.009_bib43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jobcr.2021.02.009_bib44","first-page":"1338","article-title":"Successful treatment of pemphigus vulgaris with ofatumumab","volume":"17","author":"Rapp","year":"2018","journal-title":"J\u00a0Drugs Dermatol JDD: J Drugs Dermatol JDD"},{"issue":"12","key":"10.1016\/j.jobcr.2021.02.009_bib45","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamadermatol.2014.1939","article-title":"Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris","volume":"150","author":"Ellebrecht","year":"2014","journal-title":"JAMA dermatology"},{"issue":"4","key":"10.1016\/j.jobcr.2021.02.009_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/ken476","article-title":"Update on immunotherapy for systemic lupus erythematosus\u2014what\u2019s hot and what\u2019s not!","volume":"48","author":"Karim","year":"2009","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jobcr.2021.02.009_bib47","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar1942","article-title":"Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus","volume":"8","author":"D\u00f6rner","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.jobcr.2021.02.009_bib48","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/imt.13.94","article-title":"Current immunotherapy in rheumatoid arthritis","volume":"5","author":"Meier","year":"2013","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jobcr.2021.02.009_bib50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"}],"container-title":["Journal of Oral Biology and Craniofacial Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212426821000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212426821000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:27:20Z","timestamp":1761946040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212426821000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2212426821000257"],"URL":"https:\/\/doi.org\/10.1016\/j.jobcr.2021.02.009","relation":{},"ISSN":["2212-4268"],"issn-type":[{"value":"2212-4268","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral Biology and Craniofacial Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jobcr.2021.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Craniofacial Research Foundation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}